Switch to Dark

Pricing

Learn

MRK - Merck & Co Inc

386

$114.69

$0.49 (0.429%)

3/20/26, 3:23 PM

Score

3.79/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

MRK

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$283.60B

Industry

Pharmaceuticals

EPS (TTM)

$7.33

P/E (TTM)

15.54

Div & Yield

$3.40 (2.96%)

FCF Payout Ratio

68.02%

P/S (TTM)

4.36

P/B

5.39

Diluted Shares

2.49B

Ex-Dividend

2026-03-16

Next Earnings

04-30

Forward P/E

21.18

Payout Ratio

46.06%

P/FCF (TTM)

22.94

FCF Yield

4.36%

Earnings Yield

6.44%

52 Week Range

Score Card

Explore Scores Tab

3.79

Good

Merck & Co Inc has grown revenue at 1.31% over the past year, which suggests sales are increasing. Also, it has seen its diluted average shares outstanding decrease by -1.85% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

4.00

Good

Profitability

2.00

Bad

Fin. Health

4.00

Good

Dividends

3.00

Average

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-03-12 13:52:51

Form 10-K

Annual financials report pursuant to Section 13 or 15(d)

Filed on 2026-02-24 16:15:30

Form 13F-HR

Unknown Form Type

Filed on 2026-02-17 16:01:41

Form 144/A

Unknown Form Type

Filed on 2026-02-13 16:15:23

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-12 16:02:53

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-10 16:38:04

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-10 16:04:14

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-09 16:57:21

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-09 16:55:43

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-09 16:04:59

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-09 16:01:25

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-06 16:35:15

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$157.50

37.3%

Avg:

$128.08

11.7%

Low:

$95.95

-16.3%

(% change is relative to the current stock price: $114.69)

Analyst Recommendations

Go to Analyst Tab

3.89

Good

22%

Strong Buy (8)

44%

Buy (16)

33%

Hold (12)

Sell (0)

Strong Sell (0)

About

Website
https://www.merck.com/
Address
126 East Lincoln Avenue, P.O. Box 2000, Rahway NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=310158

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

IPO Date

1941-01-01

Industry

Pharmaceuticals

Total Employees

75,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

Switch to Dark

Pricing

Learn

MRK - Merck & Co Inc

386

$114.69

$0.49 (0.429%)

3.79/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form 3

Filed on 2026-03-12 13:52:51

Form 10-K

Filed on 2026-02-24 16:15:30

Form 13F-HR

Filed on 2026-02-17 16:01:41

Form 144/A

Filed on 2026-02-13 16:15:23

Form 4

Filed on 2026-02-12 16:02:53

Form 144

Filed on 2026-02-10 16:38:04

Form 4

Filed on 2026-02-10 16:04:14

Form 144

Filed on 2026-02-09 16:57:21

Form 144

Filed on 2026-02-09 16:55:43

Form 4

Filed on 2026-02-09 16:04:59

Form 4

Filed on 2026-02-09 16:01:25

Form 144

Filed on 2026-02-06 16:35:15

Financials

Price Targets

37.3%

11.7%

-16.3%

Analyst Recommendations

About

Similar Stocks